The DOI matches its Crossref record; 311 of the 317 references it cites were found in a registry or an index; 172 of the 310 sources its claims cite were checked for support.
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Open accessAbstract
Despite recent advances in the treatment of obesity, lifestyle medicine remains foundational to the treatment of individuals with obesity, regardless of the modality chosen by the patient with the guidance of the clinician they are working with, including in conjunction with, as appropriate, anti-obesity medications and metabolic surgery. Lifestyle medicine involves the use of diet, exercise, sleep, stress, and other lifestyle modalities in the treatment of disease. Clinicians and health systems should, after a patient-centered discussion with the patient, do their best to ensure access to lifestyle treatments. Gold standard guidelines recommend intensive, multicomponent lifestyle change programs for obesity treatments with evidence-based diet and exercise counseling and established, theoretically driven behavior change components. Clinicians treating obesity should be aware of their own biases, make efforts to reduce stigmatizing experiences in their practice, and address weight stigma in their treatment plans as needed. A variety of dietary patterns can be used to support patients with obesity, and clinicians should make evidence-based but patient-centered recommendations that aim to maximize adherence. Diet and exercise can play an important role in reducing the side effects of treatment and optimizing outcomes in weight loss, attenuating the effects of metabolic adaptation, and weight maintenance. Exercise should be increased gradually to reduce injury with a goal of 200–300 min (approximately 3.3–5 h) of moderate to vigorous intensity exercise per week to maximize weight maintenance effects with exercise prescriptions customized to patients risks. A variety of practice models can be leveraged along with the use of an interdisciplinary team to provide lifestyle medicine care for those with obesity.
Overview
CoChat Summary
TL;DR
This narrative review argues that lifestyle medicine remains foundational to obesity treatment even in the era of highly effective anti-obesity medications and metabolic surgery, and provides a clinically actionable framework covering nutrition, exercise, behavior change, sleep, stress, and stigma reduction. It emphasizes that lifestyle intervention should be offered alongside, not withheld before, pharmacotherapy or surgery, and that multidisciplinary care models are needed to improve access.
Key findings
- Lifestyle intervention alone produces clinically significant weight loss of 5–10% of initial body weight, with large studies and RCTs averaging 4–6%; patients needing more weight loss may require medications or surgery.
- The Diabetes Prevention Program showed a 58% risk reduction in developing type 2 diabetes over 2.8 years in patients with overweight/obesity and prediabetes; the DPP Outcomes Study showed protection from diabetes progression despite weight regain.
- Pairing medication with intensive lifestyle intervention may improve outcomes: the MODEL-IBT study produced close to 12% weight loss with liraglutide plus intensive behavioral therapy (vs. 6–8% average in liraglutide trials), and SURMOUNT-3 showed 25% weight loss with tirzepatide in patients who had already achieved ≥5% weight loss with intensive lifestyle intervention.
- Exercise targets: 200–300 min/week of moderate-to-vigorous activity to maximize weight maintenance; 225–420 min/week of aerobic activity for meaningful weight and adiposity loss; >150 (preferably up to 250–300) min/week to prevent weight regain. Fat-free mass loss from GLP-1 RA medications is estimated at 25–40% of total weight loss, motivating protein intake and resistance training.
Methods
- Narrative/expert review intended for primary care clinicians, lifestyle medicine practitioners, and obesity specialists; the authors state it is grounded in current guidelines and provides summary tables and patient-centered strategies.
- No systematic search strategy, inclusion criteria, or formal evidence appraisal is described; the paper synthesizes guideline statements, RCTs, cohort studies, and mechanistic literature across sections on diet, exercise, sleep, stress, stigma, medications, surgery, and care delivery models.
- Rarer causes of obesity (monogenic, syndromic, hypothalamic) are explicitly stated to be out of scope.
Limitations
- Stated: the review is narrative and non-systematic; rarer obesity causes are excluded; several recommendations are explicitly labeled as the authors' experience or position rather than evidence (e.g., fiber for GLP-1 RA side effects, self-monitoring suggestions, inclusive "movement" terminology).
- Stated: evidence gaps are acknowledged in several areas — little evidence to guide physical activity counseling that reduces stigma, unclear weight-loss outcomes for shared medical appointments, limited research on NEAT interventions for weight maintenance, and unclear long-term benefits/safety of fasting-mimicking diets.
- Evident from the text: no formal risk-of-bias assessment or quantitative synthesis is performed, and many cited sources are guidelines, prior reviews, and small or single trials, so effect estimates are reported as cited rather than independently verified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
118 Valid · 6 Not valid · 53 Not checked · 20 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Acute exercise can cause reductions in overall energy intake that can cause weight gain”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 10. The Role of Physical Activity in Obesity Treatment > 10.1. Role of Aerobic Exercise in Obesity Treatment
What the sources say
- Disputedcites [240] Funabashi, 2024, Acute Vigorous Exercise Decreases Subsequent Nonexercise Physical Activity and Body Temperature Linked to Weight Gain, Med. Sci. Sports Exerc. sourceExperimental — accuracy not yet measured
The Discussion ('Contributions of NEPA and body temperature'; page not provided) reports weight gain without increased food intake and links energy compensation to reduced nonexercise physical activity and body temperature. The paper identifies reduced energy expenditure—not reduced energy intake—as the relevant mechanism; its background discussion describes increased energy intake as a possible compensatory response. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Though clear weight loss outcomes are still to be determined”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 12. Clinical Models to Support Lifestyle Medicine Treatment Access for Patients with Obesity > 12.1. Shared Medical Appointments
What the sources say
- Disputedcites [290] Shibuya, 2020, Association between shared medical appointments and weight loss outcomes and anti-obesity medication use in patients with obesity, Obes. Sci. Pract. sourceExperimental — accuracy not yet measured
The Results section reports significantly greater weight loss in the SMA group than in the matched non-SMA group at 6 months, 1 year, and 2 years. The Discussion describes the SMA group's weight-loss outcomes as superior. The paper calls for further research, but it does not say that weight-loss outcomes remain undetermined. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [291] Kirbach, K., Marshall-Moreno, I., Shen, A., Cullen, C., Sanigepalli, S., Bobadilla, A., MacElhern, L., Grunvald, E., Kallenberg, G., and Tristão Parra, M. (2024). Implementation of a virtual, shared medical appointment program that focuses on food as medicine principles in a population with obesity: The SLIM program. Front. Nutr., 11. sourceExperimental — accuracy not yet measured
The Methods (Outcome measures and data analysis) assess attendance rather than weight loss, and the Discussion says an effectiveness study is planned; weight-loss outcomes for the SLIM program therefore remain undetermined. The claim is broader than that program, however: the Introduction reports that patients attending weight-management SMAs have sustained significantly more weight loss than a comparator group. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [294] Yager, 2020, Evaluation of multidisciplinary weight loss shared medical appointments, J. Am. Pharm. Assoc. source
- Not matchedcites [295] American Academy of Family Physicians (2022, January 18). Shared Medical Appointments/Group Visits. Available online: https://www.aafp.org/about/policies/all/shared-medical-appointments.html.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lifestyle intervention can also reduce side effects in patients taking GLP-1 receptor agonists including recommending smaller (and if needed, more frequent) meals that are lower in fat [14,86].”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 7. The Role of Lifestyle Medicine in the Era of GLP-1 RA and Other Anti-Obesity Medications > 7.1. Nutrition Recommendations for Those on Anti-Obesity Medications
What the sources say
- Could not verifycites [14] Grunvald, 2022, AGA clinical practice guideline on pharmacological interventions for adults with obesity, Gastroenterology sourceExperimental — accuracy not yet measured
The Summary of the Evidence describes lifestyle interventions alongside GLP-1 receptor agonist treatment, but does not say they reduce side effects. The Implementation Considerations instead say gradual dose titration may mitigate nausea and vomiting; searches for smaller, more frequent, or lower-fat meals found no such advice for GLP-1 receptor agonists in our copy. (LLM, conf=0.76)
- Partly supportedcites [86] Das, 2020, 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes, J. Am. Coll. Cardiol. sourceExperimental — accuracy not yet measured
In “What to Monitor When Prescribing a GLP-1RA,” the consensus says eating smaller portions and following a low-fat diet can help minimize nausea and vomiting. It does not recommend eating more frequently, even if needed. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, the SURMOUNT-3 study showed weight loss of 25% of initial body weight after receiving tirzepatide in patients who had already achieved greater than or equal to 5% weight loss with intensive lifestyle intervention [85].”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 7. The Role of Lifestyle Medicine in the Era of GLP-1 RA and Other Anti-Obesity Medications
What the sources say
- Supportedcites [85] Wadden, 2023, Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial, Nat. Med. source
The Results (Secondary outcomes; page unavailable) report a total weight reduction of 24.3% from the start of intensive lifestyle intervention through 72 weeks of tirzepatide, reasonably described as about 25% of initial body weight. The Main section confirms that participants had first lost at least 5% during the lifestyle-intervention lead-in. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“in the MODEL-IBT study, in which liraglutide combined with intensive behavioral therapy produced close to 12% weight loss [51]”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 7. The Role of Lifestyle Medicine in the Era of GLP-1 RA and Other Anti-Obesity Medications
What the sources say
- Supportedcites [51] Wadden, 2019, A Protocol to Deliver Intensive Behavioral Therapy (IBT) for Obesity in Primary Care Settings: The MODEL-IBT Program, Obesity source
The ‘Summary of study results’ section reports that the IBT-liraglutide group lost a mean of 11.5% of initial weight at 52 weeks—close to 12%. The paper identifies this trial as the MODEL trial in ‘Combining CMS’ IBT Benefit with the DPP Protocol.’ (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
109 more claims · 62 with their cited sources checked
Create a free account to see all 197 claims and to verify the 2 references still open.
- It may state two separate claims as one. 65
- Probably not a substantial claim. 21
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 10. The Role of Physical Activity in Obesity Treatment > 10.1. Role of Aerobic Exercise in Obesity Treatment
“Acute exercise can cause reductions in overall energy intake that can cause weight gain”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 9. The Role of Diet in the Treatment of Obesity
“Weight loss is induced by maintaining an energy deficit through the reduction of caloric intake, an increase in energy expenditure through physical activity, or, ideally, a combination of both.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 6. The Effect of Weight Stigma in Healthcare and Its Impact on the Treatment of Obesity
“Weight stigma has been linked to lower morbidity and mortality.”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 6. The Effect of Weight Stigma in Healthcare and Its Impact on the Treatment of Obesity
“These judgements and behaviors can lead to decreased access to care, delay in seeking care, and strained patient–provider relationships, all of which contribute to poor medical outcomes.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 6. The Effect of Weight Stigma in Healthcare and Its Impact on the Treatment of Obesity
“For example, the Diabetes Prevention Program outcomes study (DPPOS) showed protection from progression to diabetes despite weight regain [55].”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > References
“55. Puhl R.M. Weight Stigma and Barriers to Effective Obesity Care Gastroenterol. Clin. 2023 52 417 428 10.1016/j.gtc.2023.02.002 37197883”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > 4. Role of Other Lifestyle Medicine Pillars
“This is elucidated in the Wisconsin sleep cohort study where reductions in slow-wave (N3) and REM sleep, which are key components of restorative sleep, are associated with weight gain and obesity [40].”
§ Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment > References
“40. Georgoulis M. Yiannakouris N. Kechribari I. Lamprou K. Perraki E. Vagiakis E. Kontogianni M.D. Dose-response relationship between weight loss and improvements in obstructive sleep apnea severity after a diet/lifestyle interventions: Secondary analyses of the “MIMOSA” randomized clinical trial”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“Table 3 contains links to freely available IBT curricula [48].”
InfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 1×
“Sarcopenia is defined as an age-or disease-related loss of healthy muscle mass and function [248,249].”
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361601 · Cited by 5,981
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Driving some of this is the efficacy of the medications, with semaglutide showing ~14% weight loss in clinical trials, and tirzepatide demonstrating ~20% weight loss in clinical trials [78,79].”
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“…be noted that lifestyle change interventions provide an expected weight loss between 5 and 10% [17,152] with the potential for significant weight regain [95], though as seen in the diabetes prevention program outcomes study, cardiometabolic benefits may be preserved despite weight regain [153].”
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544 · cited 1×
“Meanwhile, in 2024, the NCD Risk Factor Collaboration (NCD-RisC) [3] published findings which estimate that more than one billion people in the world are now living with obesity, (nearly 880 million adults and 159 million children and adolescents aged 5–19 years).”
Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Miller, N. H., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437740.48606.d1 · Cited by 2,261
Research works printed but not linked: 4
- Farhana, A., and Rehman, A. (2025, March 28). Metabolic Consequences of Weight Reduction, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK572145/.
- Hui, C., and Bauza, G.J. (2025, April 12). Dumping Syndrome, StatPearls, Available online: http://www.ncbi.nlm.nih.gov/books/NBK470542/.
- Hoelscher, D.M., Tobias, D., Deierlein, A., Gardner, C., Giovannucci, E., Anderson, C.A.M., Booth, S., Raynor, H., Fung, T., and Stanford, F.C. (2025, June 29). Dietary Patterns and Growth, Body Composition, and Risk of Obesity: A Systematic Review, Available online: https://www.ncbi.nlm.nih.gov/books/NBK611726/.
- IQWiG (2025, June 09). In brief: Physical therapy, InformedHealth.org [Internet], Available online: https://www.ncbi.nlm.nih.gov/books/NBK561514/.
Cited by
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
“Lifestyle interventions also vary substantially in intensity and design, ranging from general lifestyle advice to structured, multidisciplinary programmes that combine dietary modification, physical activity and behavioural counselling; such intensive multimodal interventions have demonstrated [37].”
Therapeutic Potential of White Kidney Beans (Phaseolus vulgaris) for Weight Management
Muzaffar, H., Jehangir, M., Hu, J., Yu, Y., Yu, M., & Hu, Y. (2025) · Foods · doi:10.3390/foods14223940 · Cited by 5
“It also effectively regulates energy intake and appetite, thereby demonstrating promising outcomes in clinical studies involving obese patients, as illustrated in Figure 1 [27].”
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Dietary strategies to counter obesity-accelerated aging: Enhancing health-span and longevity
Rao, P. P. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100702 · Cited by 1
Khormi, K. A., Mumena, W. A., Salman, A. K. M., Faden, A. A., Hafiz, M. S., & Kutbi, H. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124571 · Cited by 1
“These strategies are widely recommended as first-line approaches for weight reduction and improving metabolic health [15,16].”
Metadata
- Authors
- Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., Le, C., Rajan, S., & Romero, C.
- Affiliations
- University of California San Diego (US)
- Stanford Medicine (US)
- UC San Diego Health System (US)
- UConn Health (US)
- Department of Practice Management, American College of Lifestyle Medicine, Chesterfield, MO 63006, USA
- Department of Clinical Services, Enara Health, San Mateo, CA 94403, USA
- San Diego State University (US)
- Corresponding author
- Sannidhi, Deepa
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-07-21
- Volume
- 17
- Issue
- 14
- Pages
- 2382
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12300522
- OpenAlex
- W4412526707
- Cited by
- 29
- References
- 317
- Citations by year
- 2026: 27 · 2025: 2
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ardmore Institute of Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity and Health Practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- lifestyle medicine, obesity, anti-obesity drugs, metabolic surgery, nutrition counseling, exercise prescription, weight maintenance, weight loss, weight cycling, metabolic adaptation, weight stigma, behaviour change interventions, patient-centered care, dietary habits, sleep, stress, multidisciplinary care, access barriers
- MeSH terms
- Healthy Lifestyle, Obesity Management, Diet, Reducing, Humans, Obesity, Patient Care Team, Patient Compliance, Exercise, Patient-Centered Care, Anti-Obesity Agents, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment. https://app.cochat.ai/papers/10.3390/nu17142382
- The paper
- Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., Le, C., Rajan, S., & Romero, C. (2025). Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment. Nutrients. https://doi.org/10.3390/nu17142382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
